MedTrace Logo

Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic

NCT00929292 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2009-06-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the nutritional adequacy, the digestive tolerance and the effect on colic of an alpha-lactalbumin-enriched and probiotic-supplemented infant formula.

Conditions

  • Growth
  • Colic

Interventions

OTHER

Modilac Dahlia 1

Infant formula used for non breastfed children with colic

OTHER

Modilac 1

Infant formula used for non breastfed children

Sponsors & Collaborators

  • Sodilac

    lead INDUSTRY

Principal Investigators

  • Christophe Dupont, PhD · Hôpital Saint Vincent de Paul

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Weeks
Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929292 on ClinicalTrials.gov